

## Total Synthesis of ( $\pm$ )-Prostaglandin D<sub>1</sub>: Use of Triethylsilyl Protecting Groups†


By TERANCE W. HART, DAVID A. METCALFE, and FEODOR SCHEINMANN\*

(The Ramage Laboratories, Department of Chemistry and Applied Chemistry, University of Salford, Salford M5 4WT)

**Summary** ( $\pm$ )-Prostaglandin D<sub>1</sub> has been synthesised by oxidation of ( $\pm$ )-PGF<sub>1 $\alpha$</sub>  15-t-butyl dimethylsilyl ether and also of its 9-triethylsilyl ether; preparation and selective hydrolysis of triethylsilyl ethers are key steps in the sequence.

THE biosynthetic and structural studies associated with PGD<sub>1</sub> [(15*S*, 13*E*)-9 $\alpha$ ,15-dihydroxy-11-oxoprost-13-enoic acid] (**1**) were well described by 1972,<sup>1</sup> but since then there have been only a few reports on the chemistry and properties of this metabolite.<sup>2</sup> The total synthesis of PGD<sub>1</sub> is now described which involves oxidation studies on PGF<sub>1 $\alpha$</sub>  derivatives. The triethylsilyl group has been used to regioselectively protect and unmask hydroxy groups at C-9 and C-11. Previous work associated with the synthesis of PGD<sub>2</sub> involved non-selective oxidation of the C-9 and C-11 hydroxy groups of PGF<sub>2 $\alpha$</sub>  derivatives,<sup>3</sup> or lengthy sequences for protection at C-9 prior to oxidation at C-11.<sup>4</sup>

The synthesis of PGD<sub>1</sub> involves preparation of ( $\pm$ )-PGE<sub>1</sub> derivatives by conjugate addition of the organo-cuprate (**4**) to the trimethylsilyl ether (**2**) of the known 4-hydroxycyclopentenone (**3**).<sup>5,6</sup> Quenching the resulting enolate ion with




† The reactions were carried out with racemates to give ( $\pm$ )-prostaglandins and their ( $\pm$ )-15-epimers. However, since the starting materials (**2**) and (**3**) have been resolved, our sequence allows an asymmetric convergent synthesis of PGD<sub>1</sub>.

ammonium sulphate in a two-phase ether-aqueous system allowed both silyl protecting groups at C-11 and C-15 to be retained. The PGE<sub>1</sub> derivative (5) was purified by dry column chromatography<sup>7</sup> (ethyl acetate-toluene, 1:3;  $R_F$  0.64) and reduced with sodium borohydride<sup>8</sup> to give a 3:1 mixture of PGF<sub>1 $\alpha$</sub>  and PGF<sub>1 $\beta$</sub>  methyl esters protected only at C-15 (6a and 6b). Isolation of the 9 $\alpha$ -isomer (6a) by dry column chromatography (ethyl acetate-toluene, 1:1;  $R_F$  0.29) followed by saponification (10% sodium hydroxide in 50% aqueous methanol at 20 °C for 2.5 h) gave PGF<sub>1 $\alpha$</sub>  15-t-butyldimethylsilyl ether (7).

Regioselective oxidation at C-11 requires prior protection of the hydroxy group at C-9. Thus trimethylsilylation of the ester (6a) at C-11 with trimethylsilyldiethylamine<sup>9</sup> in acetone at -40 °C followed by triethylsilylation at C-9 with triethylsilyldiethylamine-triethylchlorosilane (10:1) at 20 °C for 20 h gives the fully protected PGF<sub>1 $\alpha$</sub>  derivative (8; 80%). Selective hydrolysis of the trimethylsilyl group using tetrahydrofuran (THF)-AcOH-H<sub>2</sub>O (8:8:1) for 1.0 h at 20 °C gives the required intermediate (9; R = Me, 92%). Reaction with Jones reagent at -30 °C<sup>3</sup> followed by mild acid hydrolysis using AcOH-H<sub>2</sub>O-THF (65:35:10) at 45 °C for 2.5 h gives the PGD<sub>1</sub> methyl ester (58%).

A more attractive and shorter route involves use of the same protecting group in the ring followed by selective hydrolysis. Thus ( $\pm$ )-PGF<sub>1 $\alpha$</sub>  15-t-butyldimethylsilyl ether (7) was conveniently protected (see 10) by triethylsilylation at C-1, C-9, and C-11 by treatment with triethylsilyl chloride in pyridine at 60 °C for 0.5 h (95%). Careful hydrolysis with THF-AcOH-H<sub>2</sub>O (8:8:1) at 20 °C for 4 h cleaved the ester group and favoured hydrolysis (9; R = H) at C-11 (76%) over formation of the PGF<sub>1 $\alpha$</sub>  derivative (7; 21%). Oxidation with Jones reagent or better, buffered pyridinium chlorochromate, to give (11; 75%) followed by removal of both protecting groups at C-9 and C-15 with THF-AcOH-H<sub>2</sub>O (10:65:35) at 45 °C for 3 h gives ( $\pm$ )-



PGD<sub>1</sub> (1; 75%), m.p. 75–77 °C,  $R_F$  0.48, identical with an authentic material, and ( $\pm$ )-15-*epi*-PGD<sub>1</sub> (88%),  $R_F$  0.52, which were separated by t.l.c. (ethyl acetate-formic acid, 80:1). Since the triethylsilyl group at C-11 is selectively removed under mild acidic conditions, hydrolysis in the presence of an oxidising agent will give the 11-oxo-derivative (11). Thus reaction of the ( $\pm$ )-PGF<sub>1 $\alpha$</sub>  9,11-bistriethylsilyl ether (10) or its corresponding acid with a stoichiometric two-fold excess of pyridinium chlorochromate and sodium acetate (2:1, w/w) in dichloromethane at 20 °C gives the PGD<sub>1</sub> derivative (11; 80%). The triethylsilyl protecting group has been similarly utilized in a synthesis of PGD<sub>2</sub>.<sup>10</sup>

We thank the Medical Research Council and the National Research Development Corporation for financial support (to T. W. H. and D. A. M.) and Dr. R. L. Jones for authentic samples and some mass spectral analysis.

(Received, 2nd October 1978; Com. 1047.)

<sup>1</sup> P. S. Foss, C. J. Sih, C. Takeguchi, and H. Schnoes, *Biochemistry*, 1972, **11**, 2271; E. Granstrom, W. E. M. Lands, and B. Samuelsson, *J. Biol. Chem.*, 1968, **243**, 4104; D. H. Nugteren, R. K. Beerthuis, and D. A. Van Dorp, *Rec. Trav. chim.*, 1966, **85**, 405.

<sup>2</sup> P. Falardeau, M. Hamberg, and B. Samuelsson, *Biochim. Biophys. Acta*, 1976, **441**, 193; R. L. Jones, 'Pharmacology of the prostaglandins,' in 'Prostaglandin Research,' ed. P. Crabbe, Academic Press, New York, 1977, p. 65; 'Advances in Prostaglandin and Thromboxane Research,' eds. B. Samuelsson and R. Paoletti, Raven Press, New York, 1976, Vol. 1, p. 221; J. A. Chan, M. Nagassawa, C. Takeguchi, and C. J. Sih, *Biochemistry*, 1975, **14**, 2987; R. J. Flower, E. A. Harvey, and W. P. Kingston, *British J. Pharmacol.*, 1976, **56**, 229; D. I. Wilkinson and J. T. Walsh, *J. Invest. and Dermatol.*, 1976, **68**, 210.

<sup>3</sup> M. Hayashi and T. Tanouchi, *J. Org. Chem.*, 1973, **38**, 2115; E. F. Jenny, P. Schaublein, H. Fritz, and H. Fuhrer, *Tetrahedron Letters*, 1974, 2235.

<sup>4</sup> N. H. Andersen, S. C. Imamoto, and D. H. Picker, *Prostaglandins*, 1977, **14**, 61.

<sup>5</sup> R. Pappo, P. Collins, and C. Jung, *Tetrahedron Letters*, 1973, 943.

<sup>6</sup> C. J. Sih, J. B. Heather, R. Sood, P. Price, G. Peruzzotti, L. F. Hsu Lee, and S. S. Lee, *J. Amer. Chem. Soc.*, 1975, **97**, 865.

<sup>7</sup> B. Loev and M. Goodman, in 'Progress in Separation and Purification,' vol. III, eds. E. S. Perry and C. J. Van Oss, Wiley-Interscience, New York, 1970, p. 73.

<sup>8</sup> D. R. White, U.S.P. 3745178 (1973); W. P. Schneider, U.S.P. 3758542, (1973); A. Guzman and J. M. Muchowski, *Tetrahedron Letters*, 1975, 2053.

<sup>9</sup> E. W. Yankee, C. H. Lin, and J. Fried, *J.C.S. Chem. Comm.*, 1972, 1120; I. Weisz, K. Felfoldi, and K. Kovacs, *Acta Chim. Acad. Sci. Hung.*, 1968, **58**, 189.

<sup>10</sup> T. W. Hart and F. Scheinmann, unpublished work.